Since previous BSH guidelines covering investigation and management of thrombocytosis, there have been considerable advances in the biology, diagnosis and management of essential thrombocythaemia (ET), particularly relating to myeloproliferative neoplasm (MPN) driver mutations in JAK2, CALR and MPL.
However, many patients with unexplained thrombocytosis are negative for these mutations. Optimal application and interpretation of bone marrow biopsy and broader genomic testing have not been defined in this context and real-world practice varies.
This guideline provides expert consensus on investigation and management of patients with thrombocytosis lacking classical MPN driver mutations, focusing on practical diagnostic and management strategies appropriate for UK haematology practice.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this good practice paper. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.